In this article, we will take a look at the top 5 stock picks of Lawrence Kam’s Sonic Capital. If you want to read our comprehensive analysis of the history, investment philosophy, and hedge fund preference of Lawrence Kam’s Sonic Capital, you can head over to Top 10 Stock Picks of Lawrence Kam’s Sonic Capital.
5. Regenxbio Inc (NASDAQ:RGNX)
Sonic Capital’s Stake Value: $7.914 million
Percentage of Sonic Capital’s 13F Portfolio: 4.47%
Number of Hedge Fund Holders as of Q3 2021: 15
Regenxbio Inc (NASDAQ: RGNX) is a biotechnology company that specializes in genetics and works to produce techniques to treat serious, incurable diseases using recombinant adeno-associated virus (AAV) gene therapy. The company has its headquarters in Rockville, Maryland, and was founded in 2008 by Kenneth T. Mills and James M. Wilson. Sonic Capital held 188,786 shares in Regenxbio Inc (NASDAQ: RGNX) as of Q3 2021, which were valued at over $7.9 million.
On November 2, the company shared its earnings report for Q3 2021. Regenxbio Inc (NASDAQ: RGNX)’s revenue for the third quarter of 2021 was $30.77 million, which missed estimates by $2.4 million.
4. United Airlines Holdings Inc (NYSE:UAL)
Sonic Capital’s Stake Value: $8.172 million
Percentage of Sonic Capital’s 13F Portfolio: 4.61%
Number of Hedge Fund Holders as of Q3 2021: 39
United Airlines Holdings Inc (NYSE: UAL) is an airline holding company that operates United Airlines, Inc. The company is headquartered in the Willis Tower in Chicago and provides air transport services by managing a complex network of both domestic and international flights. The airline offers both passenger travel and cargo shipping services and operates in 48 countries around the world.
On October 19, United Airlines Holdings Inc (NYSE: UAL) reported its Q3 2021 revenue of $7.75 billion and Q3 EPS of $1.44. The company’s revenue showed year-over-year growth of 211.2% and beat estimates by $110 million while its EPS beat estimates by $2.81. On October 21, Helane Becker, an analyst at Cowen, raised the price target on United Airlines Holdings Inc (NYSE: UAL) to $78 from $72 and maintained a “Market Outperform” rating on the company’s shares.
3. SeaWorld Entertainment Inc (NYSE:SEAS)
Sonic Capital’s Stake Value: $8.298 million
Percentage of Sonic Capital’s 13F Portfolio: 4.68%
Number of Hedge Fund Holders as of Q3 2021: 41
SeaWorld Entertainment Inc (NYSE: SEAS) was established back in 1959 and is based in Orlando, Florida. SeaWorld Entertainment Inc (NYSE: SEAS) is a holding company for SeaWorld Parks & Entertainment, which is a theme park and entertainment company. Through its subsidiary, SeaWorld Entertainment Inc (NYSE: SEAS) owns and operates several recreational facilities such as water parks and theme parks throughout the United States.
The company announced its Q3 earnings on November 9 this year. SeaWorld Entertainment Inc (NYSE: SEAS)’s Q3 revenue of $521.2 million showed year-over-year growth of 391.2% but missed estimates by $15.35 million. In the same way, the company’s Q3 EPS of $1.28 missed consensus by $0.31. However, on November 10, Steven Wieczynski, an analyst at Stifel, raised his price target on SeaWorld Entertainment Inc (NYSE: SEAS) to $82 from $79 and maintained a “Buy” rating on the stock.
2. Adverum Biotechnologies, Inc. (NASDAQ:ADVM)
Sonic Capital’s Stake Value: $14.218 million
Percentage of Sonic Capital’s 13F Portfolio: 8.03%
Number of Hedge Fund Holders as of Q3 2021: 14
Headquartered in Redwood City, California, Adverum Biotechnologies, Inc. (NASDAQ: ADVM) is a clinical-stage biotechnology company that specializes in gene therapy. It was formerly known as Avalanche Biotechnologies and currently has a pipeline of products that aim to treat diseases of the eye using gene therapy. Sonic Capital held 6.5 million shares of the company by the end of Q3 2021, which were valued at over $14 million.
1. Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Sonic Capital’s Stake Value: $22.677 million
Percentage of Sonic Capital’s 13F Portfolio: 12.81%
Number of Hedge Fund Holders as of Q3 2021: 10
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) is a biopharmaceutical company that was established in 1996 and is based in Durham, North Carolina. The company focuses on manufacturing Sodium Thiosulfate specifically for pediatric cancer patients. The chemical is used by cancer patients to prevent platinum-induced ototoxicity.
On November 10, the cash, cash equivalents, and short-term investments of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) for Q3 2021 were reported to be $24.3 million, while the EPS of -$0.16 beat estimates by $0.01.
You can also take a peek at Why These 10 Stocks Fell on Monday and 10 Penny Stocks With Long-Term Growth Catalysts.
